Developing a novel biomarker test in parallel with a therapeutic, with the expectation that the biomarker is going to be included in the FDA-approved label, is accompanied by a set of significant scientific and commercialization challenges.
Holy Grail Of Precision Medicine – Co-Development Of Therapeutics And Companion Diagnostics – Hasn’t Yet Achieved Its Potential
